DS Biopharma Investigational Site
Belfast, Ireland
Completed
NCT Number: NCT02673593
Safety and Efficacy Study of Orally Administered DS102 in Healthy Subjects
The purpose of the study is to investigate the safety, pharmacokinetics and food effect of DS102 (up to 2000mg single and multiple daily doses) and placebo in healthy participants.
DS102 capsules will be orally administered for up to 4 weeks, and will be compared against placebo.
The study will enrol approximately 56 adult subjects.
Completed
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–45 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 1
Primary location
About this study
There will be 7 cohorts enrolled, each consisting of 8 subjects.
Cohorts 1 - 4 will be orally administered up to 2000mg single doses of DS102 on Day 1.
Cohorts 5 - 7 will be orally administered up to 2000mg multiple daily doses of DS102 for 28 days.
The primary objective is to assess the safety and plasma pharmacokinetics of single and multiple daily oral doses of DS102.
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Subject is male or female and is aged between 18 and 45 years inclusive.
- Subject's body mass index (BMI) is between 18.0 and 30.0 kg/m2 inclusive.
- Subject is a non-smoker, has been a non-smoker for 3 months prior to screening and has a negative urine cotinine test at screening.
Exclusion criteria
- Subject has had a clinically significant illness in the 4 weeks before screening.
- Use of prescribed medication in the 2 weeks before dosing or over-the-counter preparations (including vitamins and supplements) for 1 week before dosing
- Subject has a significant history of drug/solvent abuse, or a positive drugs of abuse (DOA) test at screening or Day -1.
- Subject with a history of alcohol abuse in the opinion of the Investigator, or who currently drinks in excess of 28 units per week (males) or 21 units per week (females), whereby a unit consists of 10ml or 8mg of pure alcohol, or who have a positive alcohol urine test at screening or Day -1.
- Subject has participated in any other clinical study with an investigational drug/device within 3 months before the first day of administration of study treatment.
- Subject has a positive test for human immunodeficiency virus (HIV) antibodies, Hepatitis B surface antigen or Hepatitis C antibodies at screening.
- Subject has had a serious adverse reaction or significant hypersensitivity to any drug.
- Subject has donated blood or blood products within 3 months before screening.
- Subject has known hypersensitivity to any ingredients of the study treatment.
Treatment and study plan
DS102
DrugPlacebo
DrugPrimary outcomes
-
Safety (adverse events, laboratory tests, vital signs, ECGs) of DS102 administered as a single dose
Time frame: 14 days
Phase I study - Overall safety of product in first in man study
-
Pharmacokinetics (Plasma concentrations assessed by Cmax) of DS102 administered as a single dose
Time frame: 14 days
Phase I study - Overall PK of product in first in man study
-
Pharmacokinetics (Plasma concentrations assessed by tmax) of DS102 administered as a single dose
Time frame: 14 days
Phase I study - Overall PK of product in first in man study
-
Pharmacokinetics (Plasma concentrations assessed by AUC0-inf) of DS102 administered as a single dose
Time frame: 14 days
Phase I study - Overall PK of product in first in man study
-
Pharmacokinetics (Plasma concentrations assessed by AUClast) of DS102 administered as a single dose
Time frame: 14 days
Phase I study - Overall PK of product in first in man study
-
Pharmacokinetics (Plasma concentrations assessed by CL/F) of DS102 administered as a single dose
Time frame: 14 days
Phase I study - Overall PK of product in first in man study
-
Pharmacokinetics (Plasma concentrations assessed by Vz/F ) of DS102 administered as a single dose
Time frame: 14 days
Phase I study - Overall PK of product in first in man study
-
Pharmacokinetics (Plasma concentrations assessed by t½) of DS102 administered as a single dose
Time frame: 14 days
Phase I study - Overall PK of product in first in man study
-
Safety (adverse events, laboratory tests, vital signs, ECGs) of DS102 administered as a multiple dose for 28 days
Time frame: 42 days
Phase I study - Overall safety of product in first in man study
-
Pharmacokinetics (Plasma concentrations assessed by Cmax) of DS102 administered as a multiple dose
Time frame: 42 days
Phase I study - Overall PK of product in first in man study
-
Pharmacokinetics (Plasma concentrations assessed by tmax) of DS102 administered as a multiple dose
Time frame: 42 days
Phase I study - Overall PK of product in first in man study
-
Pharmacokinetics (Plasma concentrations assessed by AUC0-inf) of DS102 administered as a multiple dose
Time frame: 42 days
Phase I study - Overall PK of product in first in man study
-
Pharmacokinetics (Plasma concentrations assessed by AUClast) of DS102 administered as a multiple dose
Time frame: 42 days
Phase I study - Overall PK of product in first in man study
-
Pharmacokinetics (Plasma concentrations assessed by CL/F) of DS102 administered as a multiple dose
Time frame: 42 days
Phase I study - Overall PK of product in first in man study
-
Pharmacokinetics (Plasma concentrations assessed by Vz/F) of DS102 administered as a multiple dose
Time frame: 42 days
Phase I study - Overall PK of product in first in man study
-
Pharmacokinetics (Plasma concentrations assessed by AUC 0-24) of DS102 administered as a multiple dose
Time frame: 42 days
Phase I study - Overall PK of product in first in man study
-
Pharmacokinetics (Plasma concentrations assessed by Css) of DS102 administered as a multiple dose
Time frame: 42 days
Phase I study - Overall PK of product in first in man study
-
Pharmacokinetics (Plasma concentrations assessed by t½) of DS102 administered as a multiple dose
Time frame: 42 days
Phase I study - Overall PK of product in first in man study
Sponsors and collaborators
Lead sponsor
DS Biopharma
Industry
Registry information
Official study title
A Randomised, Double-Blind, Placebo-Controlled, Single Ascending Dose and Multiple Dose Phase I Study to Assess the Safety, Pharmacokinetics and Effect of Food on Orally Administered DS102 in Healthy Subjects
Important dates
- Study start
- 2015
- Primary completion
- 2015
- Study completion
- 2015
- First posted
- Feb 4, 2016
- Registry last updated
- Feb 4, 2016
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Completed
Interhemispheric Connectivity and Compensation
NCT05207878
Healthy, Peripheral Nerve Injury Upper Limb
St Louis, Missouri, United States
View Trial Details
Completed
Physical Activity, Alzheimer's Disease and Cognition Relative to APOE Genotype
NCT03876314
Alzheimer Disease, Behavior
Greensboro, North Carolina, United States
View Trial Details
Completed
AI-driven Multiple Interactive Teaching Model on Nuclear Medicine Students' Theoretical Knowledge and Practical Skills
NCT07778186
Healthy, Nuclear Medicine Undergraduate Medical Education
Chengdu, Sichuan, China
View Trial Details
Completed
Topical Tripelennamine 1% Cream Versus Diphenhydramine 1% Cream for the Relief of Histamine-Induced Itching: A Proof Concept Study in Healthy Adults.
NCT07778472
Healthy, Pathological Conditions, Signs and Symptoms
West Palm Beach, Florida, United States
View Trial Details